

Karolinska Development portfolio company Aprea Therapeutics updates clinical data from Phase Ib trial of APR-246 in ovarian cancer

Efficacy and safety data for APR-246 in high grade serous ovarian cancer presented at ESMO 2016 annual meeting

STOCKHOLM, SWEDEN – October 10, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Aprea Therapeutics AB today presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II clinical study in collaboration with the European Network for Translational Research in Ovarian Cancer (EUTROC). The Phase Ib portion of the PiSARRO clinical study investigated the safety and efficacy of APR-246 in combination with carboplatin and pegylated liposomal doxorubicin (PLD) in patients with relapsed, p53-mutated high-grade serous ovarian cancer.

Details from the Aprea announcement follow:

The Phase Ib clinical study included 28 patients, in a 3+3 dose escalation design of APR-246 (35, 50 and 67.5 mg/kg intravenously over 6 hours on days 1-4) in combination with carboplatin AUC 5 and PLD 30 mg/m² given on day 4 of a 28-day schedule. Treatment was continued for a maximum of 6 cycles.

Results presented at ESMO showed:

- APR-246 can be combined with the standard chemotherapy at relevant doses, allowing the highest of the tested doses to be selected as the dose for continuing the trial in a randomized Phase II clinical study.
- Of 22 patients with radiologically measurable lesions, 3 had confirmed complete response, 10 had confirmed partial response, 8 had stable disease and 1 was not evaluable.
- Of 2 patients with non-measurable disease, 1 had complete response and 1 had progressive disease.
- Median progression-free survival for 22 evaluable patients, as measured by RECIST or GCIg, was 316 days (95% CI, 280-414 days) and was not influenced by the length of previous platinum treatment-free interval or dose cohort.
- APR-246 showed linear pharmacokinetics with no accumulation and low intra-patient variability. There was no indication of interaction between APR-246 and chemotherapy, supporting the combination of APR-246 with carboplatin and PLD at relevant doses.
- The most frequent treatment-emergent adverse events have been low grade GI (nausea/vomiting), CNS (dizziness and fatigue) and hematological (neutropenia and thrombocytopenia) events. The hematological side effects can be attributed to the

chemotherapy even if a contribution from the addition of APR-246 cannot be ruled out at this time.

Professor Charlie Gourley, Chair of Medical Oncology at the Edinburgh Cancer Research Center of the University of Edinburgh and clinical investigator for the study, commented, “TP53 is the gene which is most frequently altered in human cancer and is almost ubiquitously mutated in the most deadly form of ovarian cancer known as high-grade serous ovarian cancer. APR-246 targets mutated p53 protein, restoring its normal function. This study shows that APR-246 can be successfully combined with standard chemotherapy to treat high-grade serous ovarian cancer with minimal additional toxicity. The percentage of patients whose cancer responded to this treatment regime was highly encouraging and we look forward to validating these findings in a larger clinical trial.”

Dr. Mikael von Euler, Aprea Therapeutics’ Senior Vice President and Chief Medical Officer said, “We are pleased both with the results and to be able to move this drug candidate forward into a randomized Phase II clinical study. It is especially important that the patients who have more difficult-to-treat disease appear to get as much therapeutic benefit as those with less aggressive disease. The current safety profile combined with the evidence of clinical activity suggests that APR-246 might become a very important drug for patients with ovarian cancer. Furthermore, the mechanism of action suggests that APR-246 might have relevance in other tumor types and we look forward to pursuing those indications.”

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk

For Aprea Therapeutics

Christian S. Schade, President and Chief Executive Officer
chris.schade@aprea.com

Gregory A. Korb, Ph.D., Vice President of Business Development
greg.korb@aprea.com

TO THE EDITORS

About p53 and APR-246

The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors. These mutations are often associated with resistance to anticancer drugs and poor overall survival, representing a major unmet medical need in the treatment of cancer.

APR-246 has been shown to reactivate mutant p53 protein – by reconvert mutant p53 into wild-type p53 conformation and function – and thereby induce programmed cell death in human cancer cells. APR- 246 has demonstrated compelling pre-clinical antitumor activity in a wide variety of solid and hematological (blood) tumors, including ovarian cancer, small cell lung cancer, esophageal cancer and AML (acute myeloid leukemia), among others. Additionally, strong synergy has been seen with both traditional anticancer agents, such as chemotherapy, as well as newer mechanism-based anticancer drugs. In addition to pre-clinical testing, a Phase I

KAROLINSKA DEVELOPMENT

clinical study has been completed, demonstrating a favorable safety profile and both biological and clinical responses in hematological tumors with mutations in the p53 gene. The Company has commenced a Phase II study on ovarian cancer and is also expecting to begin additional clinical studies of APR-246 in other cancer indications.

About Aprea Therapeutics AB

Aprea Therapeutics AB is a Stockholm, Sweden and Boston, Massachusetts-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein, p53. The Company's lead program, APR-246, a first-in-class small molecule drug candidate, is in Phase Ib/II clinical development in ovarian cancer patients, and additional clinical studies with APR-246 in other cancer indications are planned. In March 2016, Aprea completed a EUR 46 million Series B financing with an international syndicate co-led by Versant Ventures and 5AM Ventures, with additional participation by Sectoral Asset Management, HealthCap, acting as local lead investor, and existing investor, Karolinska Development. For more information, please visit www.apreatherapeutics.com.

About Karolinska Development AB

Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients' lives and provide an attractive return on investment.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of 10 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com